News | December 12, 2025
FDA nods spotlight precision oncology platforms as market surges towards $212 billion by 2034
The U.S. oncology market is projected to soar from $81 billion in 2025 to $212 billion by 2034
The U.S. oncology market is projected to soar from $81 billion in 2025 to $212 billion by 2034
The approval follows strong results from Roche’s phase II NOBILITY and phase III REGENCY studies
Captured microbes are then neutralized on engineered microbicidal surfaces
The one-time CAR T cell infusion now becomes the first and only therapy of its kind cleared for this patient population
AEF0217 is a first-in-class CB1 receptor signaling-specific inhibitor
Jaypirca is the first and only FDA-approved non-covalent (reversible) BTK inhibitor
Here's a development that aims to keep your blood pressure in check. Literally!
Health Canada’s approval was based on a comprehensive evaluation of analytical, nonclinical, and clinical data
Soficitinib is a potent and selective TYK2 inhibitor under development for multiple T-cell mediated autoimmune disorders
Abdomen-pelvis CT is the nation’s highest-volume CT category
Subscribe To Our Newsletter & Stay Updated
